Careers Intranet Login Contact

Who We Are
- About Us
  
  The Canadian VIGOUR Centre (CVC) was established in 1997 as the Canadian arm of the international VIGOUR (Virtual Coordinating Centre for Global Collaborative Cardiovascular Research) Group. The CVC is recognized for its pioneering research in …
  
  Vision, Mission, & Core Values
  
  Generate, translate and disseminate knowledge on novel diagnostic and therapeutic strategies in cardiovascular medicine acquired through collaborative research to enhance the health of the citizens of Alberta, Canada, and the world. Aligned with the University of …
  
  Faculty & Leadership
  
  The CVC Faculty are internationally recognized as Thought Leaders in their respective areas of interest, and they collectively represent a diverse field of clinical research. Our faculty are passionately dedicated to advancing the frontiers of …
  
  Collaborators
  
  The CVC has forged strong partnerships with a number of institutions and centres around the world in the pursuit of novel research directions and the advancement of cardiovascular research. The CVC takes great pride in …
  
  Training the Next Generation
  
  As a learning organization, one of the CVC’s central tenets is to engage the next generation of health professionals in a research culture that embraces curiosity, welcomes new ideas, and seeks to address key unanswered …
  
  Annual Reports
What We Do
- Thought Leadership
  
  With their depth of knowledge and experience, CVC thought leaders are able to both understand and address the multiple challenges associated with the regulatory, financial and operational aspects of clinical research. Some key elements of their research-related …
  
  Clinical Trials Management
  
  With over 20 years of experience in clinical trial operations for Phase II/III/IV, registry, and investigator initiated studies, the CVC clinical trials team has the expertise and knowledge to deliver a high quality and well …
  
  Biostatistics
  
  Biostatistics at the CVC is a collective of applied biostatisticians with diverse training, experience, and expertise. We collaborate with local, national, and international investigative teams by advising and applying statistical reasoning and methods to the …
  
  Population Health & Economic Outcomes
  
  The CVC Population Health and Economic Outcomes team is actively involved in examining population-level issues related to access, delivery, treatment, and outcomes of heart disease in Alberta and Canada. Health care administrative databases serve as …
  
  Artificial Intelligence & Machine Learning
  
  The Artificial Intelligence and Machine Learning (AI/ML) team at the CVC is working with large-scale population level datasets to uncover novel and actionable insights that can potentially assist clinical decision making. To this end, our …
  
  ECG Core Laboratory
  
  The CVC ECG Core Laboratory continues to evaluate patient data into clinically meaningful findings that have real world implications. Using quantitative data, the electrocardiogram (ECG) – a venerable but powerful biomarker – can improve the …
  
  Business Operations
  
  The business operations group is fundamental to the organizational and financial underpinnings of the CVC. Our knowledgeable team provides expert service and oversees the negotiation and administration of agreements and contracts, budget development, financial operations …
Clinical Research
- - Clinical Trials
  - Population Based Research
  Clinical Trials
  
  This page has information on the trials that the CVC is currently working on, some of which are recruiting and others that are in the follow-up or closeout phase. If you are interested in learning …
  
  Population Based Research
  
  Below you will find information about the population based research projects that are currently underway at the CVC. Through the interrogation of registries and population health data, the CVC is steadfastly dedicated to our organization’s …
Publications
- - Publications Archive
  - Chronicle Newsletter
  Publications Archive
  
  A comprehensive online repository of publications from the CVC's faculty, staff, and trainees. The publication archive can be filtered by both year and author.
  
  Chronicle Newsletter
  
  The Canadian Cardiac Chronicle newsletter features information about the CVC's current trials, upcoming projects, research highlights, and other news and updates. Read the Winter 2024 Issue of the Chronicle Here Past Issues: Fall 2024Spring 2024Winter 2023Fall 2023Spring 2023Winter …
Programs & Development
- Canadian Cardiovascular Research Collaboratory (C3)
  
  Who We Are: The Canadian Cardiovascular Research Collaboratory (C3) is a virtual clinical research network aiming to blend two fundamental elements: Collaboration Clinical research laboratory The C3 provides opportunities for collaborative individuals to identify and study important unanswered questions …
  
  Scholar Program
  
  The CVC Scholar Program is a unique training initiative designed to advance research and further understanding of cardiovascular disease through the educational and financial support of the CVC. Trainees participating in this program will have …
  
  Clinical Trials Colloquium
  
  The CVC Clinical Trials Colloquium first began in 2014 when Dr. Paul Armstrong (CVC Founding Director) and Tracy Temple (Associate Director, Clinical Trials), brought together 13 Canadian investigative sites to help: Identify major impediments to timely …
News
Contact

Home > VICTORIA > Publications

Publications

A Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial of the Efficacy and Safety of the Oral Soluble Guanylate Cyclase Stimulator: The VICTORIA Trial.
Armstrong PW, Roessig L, Patel MJ, Anstrom KJ, Butler J, Voors AA, Lam CSP, Ponikowski P, Temple T, Pieske B, Ezekowitz J, Hernandez AF, Koglin J, O’Connor CM.
JACC Heart Fail. 2018;6:96-104. doi: 10.1016/j.jchf.2017.08.013.

Baseline Features of the VICTORIA (Vericiguat Global Study in Subjects with Heart Failure with Reduced Ejection Fraction) Trial.
Pieske B, Patel MJ, Westerhout CM, Anstrom KJ, Butler J, Ezekowitz J, Hernandez AF, Koglin J, Lam CSP, Ponikowski P, Roessig L, Voors AA, O’Connor CM, Armstrong PW; VICTORIA Study Group.
Eur J Heart Fail. 2019;21:1596-1604. doi: 10.1002/ejhf.1664.

Comparing The Benefit Of Novel Therapies Across Clinical Trials: Insights from the VICTORIA Trial.
Butler J, Anstrom KJ, Armstrong PW; VICTORIA Study Group.
Circulation. 2020; 142: 717-719. doi: 10.1161/CIRCULATIONAHA.120.047086.

Vericiguat in Patients with Heart Failure and Reduced Ejection Fraction.
Armstrong PW, Pieske B, Anstrom KJ, Ezekowitz J, Hernandez AF, Butler J, Lam CSP, Ponikowski P, Voors, AA, Jia G, McNulty SE, Patel MJ, Roessig L, Koglin J, O’Connor CM; VICTORIA Study Group.
N Engl J Med. 2020;382: 1883-1893. doi: 10.1056/NEJMoa1915928.

Natriuretic Peptide and Clinical Outcomes: Vericiguat Heart Failure With Reduced Ejection Fraction Study.
Ezekowitz JA, O’Connor CM, Troughton RW, Alemayehu WG, Westerhout CM, Voors AA, Butler J, Lam CSP, Ponikowski P, Emdin M, Patel MJ, Pieske B, Roessig L, Hernandez AF, Armstrong PW.
JACC Heart Fail. 2020. doi: 10.1016/j.jchf.2020.08.008.

Clinical Outcomes and Response to Vericiguat According to Index Heart Failure Event: Insights From the VICTORIA Trial.
Lam CSP, Giczewska A, Carolyn S. P. Lam, Sliwa K, Edelmann F, Refsgaard J, Bocchi E, Ezekowitz JA, Hernandez AF, O’Connor CM, Roessig L, Patel MJ, Pieske B, Anstrom KJ, Armstrong PW; VICTORIA Study Group.
JAMA Cardiol. 2020. doi:10.1001/jamacardio.2020.6455.

Renal Function and the Effects of Vericiguat in Patients with Worsening Heart Failure with Reduced Ejection Fraction: Insights from VICTORIA (VerICiguaT Global Study in Subjects with HFrEF) Trial.
Voors AA, Mulder H, Reyes E, Cowie MR, Lassus J, Hernandez AF, Ezekowitz JA, Butler J, O’Connor CM, Koglin J, Lam CSP, Pieske B, Roessig L, Ponikowski P, Anstrom KJ, Armstrong PW; VICTORIA Study Group.
Eur J Heart Fail. 2021. doi: 10.1002/ejhf.2221.

Clinical Outcome Predictions for the VerICiguaT Global Study in Subjects With Heart Failure With Reduced Ejection Fraction (VICTORIA) Trial.
Mentz RJ, Mulder H, Mosterd A, Sweitzer NK, Senni M, Butler J, Ezekowitz JA, Lam CSP, Pieske B, Ponikowski P, Voors AA, Anstrom KJ, Armstrong PW, O’connor CM, Hernandez AF; VICTORIA Study Group.
J Card Fail. 2021. doi: 10.1016/j.cardfail.2021.05.016.

Vericiguat in Patients with Atrial Fibrillation and Heart Failure with Reduced Ejection Fraction: Insights from the VICTORIA trial.
Ponikowski P, Alemayehu W, Oto A, Bahit MC, Noori E, Patel MJ, Butler J, Ezekowitz JA, Hernandez AF, Lam CSP, O’Connor CM, Pieske B, Roessig L, Voors AA, Westerhout C, Armstrong PW; VICTORIA Study Group.
Eur J Heart Fail. 2021. doi: 10.1002/ejhf.2285.

Participation in a Heart Failure Clinical Trial: Perspectives and Opportunities From the VICTORIA Trial and VICTORIA Simultaneous Registry.
Ezekowitz J, Mentz RJ, Westerhout CM, Sweitzer NK, Givertz MM, Piña IL, O’Connor CM, Greene SJ, McMullan C, Roessig L, Hernandez AF, Armstrong PW.
Circ Heart Fail. 2021. doi: 10.1161/CIRCHEARTFAILURE.120.008242.

Hemoglobin and Clinical Outcomes in the VerICiguaT Global Study in Patients With Heart Failure and Reduced Ejection Fraction (VICTORIA).
Ezekowitz JA, Zheng Y, Cohen-Solal A, Melenovský V, Escobedo J, Butler J, Hernandez AF, Lam CSP, O’Connor CM, Pieske B, Ponikowski P, Voors AA, deFilippi C, Westerhout CM, McMullan C, Roessig L, Armstrong PW; VICTORIA Study Group.
Circulation. 2021. doi: 10.1161/CIRCULATIONAHA.121.056797.

Blood Pressure and Safety Events With Vericiguat in the VICTORIA Trial.
Lam CSP, Mulder H, Lopatin Y, Vazquez-Tanus JB, Siu D, Ezekowitz J, Pieske B, O’Connor CM, Roessig L, Patel MJ, Anstrom KJ, Hernandez AF, Armstrong PW;VICTORIA Study Group.
J Am Heart Assoc. 2021. doi: 10.1161/JAHA.121.021094.

Vericiguat in Patients with Coronary Artery Disease and Heart Failure with Reduced Ejection Fraction.
Saldarriaga C, Atar D, Stebbins A, Lewis BS, Zainal Abidin I, Blaustein RO, Butler J, Ezekowitz JA, Hernandez AF, Lam CSP, O’Connor CM, Pieske B, Ponikowski P, Roessig L, Voors AA, Anstrom KJ, Armstrong PW; VICTORIA Study Group. Eur J Heart Fail. 2022. doi: 10.1002/ejhf.2468.

Medical Therapy During Hospitalization for Heart Failure with Reduced Ejection Fraction: The VICTORIA Registry.
Greene SJ, Ezekowitz JA, Anstrom KJ, Demyanenko V, Givertz MM, Piña IL, O’Connor CM, Koglin J, Roessig L, Hernandez AF, Armstrong PW, Mentz RJ. Group. J Card Fail. 2022. doi: 10.1016/j.cardfail.2022.02.011.

Vericiguat and Health-Related Quality of Life in Patients With Heart Failure With Reduced Ejection Fraction: Insights From the VICTORIA Trial.
Butler J, Stebbins A, Melenovský V, Sweitzer NK, Cowie MR, Stehlik J, Khan MS, Blaustein RO, Ezekowitz JA, Hernandez AF, Lam CSP, Nkulikiyinka R, O’Connor CM, Pieske BM, Ponikowski P, Spertus JA, Voors AA, Anstrom KJ, Armstrong PW; VICTORIA Study Group. Circ Heart Fail. 2022. doi: 10.1161/CIRCHEARTFAILURE.121.009337.

Efficacy and Safety of Vericiguat in Patients with Heart Failure with Reduced Ejection Fraction Treated with Sacubitril/Valsartan: Insights from the VICTORIA Trial.
Senni M, Alemayehu WG, Sim D, Edelmann F, Butler J, Ezekowitz J, Hernandez AF, Lam CSP, O’Connor CM, Pieske B, Ponikowski P, Roessig L, Voors AA, Westerhout CM, McMullan C, Armstrong PW; VICTORIA Study Group. Eur J Heart Fail. 2022. doi: 10.1002/ejhf.2608.

Sequential Evaluation of NT-proBNP in Heart Failure: Insights Into Clinical Outcomes and Efficacy of Vericiguat.
Armstrong PW, Zheng Y, Troughton RW, Lund LH, J Zhang, Lam CSP, Westerhout CM, Blaustein RO, Butler J, Hernandez AF, Roessig L, O’Connor CM, Voors AA, Ezekowitz J; VICTORIA Study Group.
J Am Coll Cardiol HF. 2022. DOI: 10.1016/j.jchf.2022.04.015.

Effect of Vericiguat on Left Ventricular Structure and Function in Patients with Heart Failure with Reduced Ejection Fraction: the VICTORIA Echocardiographic Substudy.
Pieske B, Pieske-Kraigher E, Lam CSP, Melenovský V, Sliwa K, Lopatin Y, Arango JL, Bahit MC, O’Connor CM, Patel MJ, Roessig L, Morris DA, Kropf M, Westerhout CM, Zheng Y, Armstrong PW; VICTORIA Study Group.
Eur J Heart Fail. 2023 Mar 30. doi: 10.1002/ejhf.2836.

Assessment of Biomarkers of Myocardial injury, Inflammation, and Renal Function in Heart Failure With Reduced Ejection Fraction: The VICTORIA Biomarker Substudy.
Defilippi CR, Alemayehu WG, Voors AA, Kaye D, Blaustein RO, Butler J, Ezekowitz JA, Hernandez AF, Lam CSP, Roessig L, Seliger S, Shah P, Westerhout CM, Armstrong PW, O’Connor CM; VICTORIA Study Group.
J Card Fail. 2023 Apr;29:448-458. doi: 10.1016/j.cardfail.2022.12.013.

Ejection Fraction, Biomarkers, and Outcomes and Impact of Vericiguat on Outcomes Across EF in VICTORIA.
Butler J, Zheng Y, Khan MS, Bonderman D, Lund LH, deFilippi CR, Blaustein RO, Ezekowitz JA, Freitas C, Hernandez AF, O’Connor CM, Voors AA, Westerhout CM, Lam CSP, Armstrong PW; VICTORIA Study Group.
JACC Heart Fail. 2023 May;11:583-592. doi: 10.1016/j.jchf.2022.12.014.

Classification of Heart Failure Events by Severity: Insights From the VICTORIA Trial.
Felker GM, North R, Mulder H, Jones WS, Anstrom KJ, Patel MJ, Butler J, Ezekowitz JA, Lam CSP, O’Connor CM, Roessig L, Hernandez AF, Armstrong PW; VICTORIA Study Group.
J Card Fail. 2023 Jun:S1071-9164(23)00204-X. doi: 10.1016/j.cardfail.2023.04.015.

Background Medical Therapy and Clinical Outcomes From the VICTORIA Trial.
Ezekowitz JA, McMullan CJ, Westerhout CM, Piña IL, Lopez-Sendon J, Anstrom KJ, Hernandez AF, Lam CSP, O’Connor CM, Pieske B, Ponikowski P, Roessig L, Voors AA, Koglin J, Armstrong PW, Butler J; VICTORIA Study Group.
Circ Heart Fail. 2023 Jul:e010599. doi: 10.1161/CIRCHEARTFAILURE.123.010599.

Evolution of NT-proBNP During Prerandomization Screening in VICTORIA: Implications for Clinical Outcomes and Efficacy of Vericiguat.
Armstrong PW, Zheng Y, Lund LH, Butler J, Troughton RW, Emdin M, Lam CSP, Ponikowski P, Blaustein RO, O’Connor CM, Roessig L, Voors AA, Ezekowitz JA, Westerhout CM; VICTORIA Study Group.
Circ Heart Fail. 2023 Jul 28:e010661. doi: 10.1161/CIRCHEARTFAILURE.123.010661.

Age, Sex, and Outcomes in Heart Failure With Reduced EF: Insights From the VICTORIA Trial.
Lam CSP, Piña IL, Zheng Y, Bonderman D, Pouleur AC, Saldarriaga C, Pieske B, Blaustein RO, Nkulikiyinka R, Westerhout CM, Armstrong PW; VICTORIA Study Group.
JACC Heart Fail. 2023 Sep;11:1246-1257. doi: 10.1016/j.jchf.2023.06.020.

Relationship Between Baseline Electrocardiographic Measurements and Outcomes in Patients with High-risk Heart Failure: Insights from the VerICiguaT Global Study in Subjects with Heart Failure with Reduced Ejection Fraction (VICTORIA) Trial.
Yogasundaram H, Zheng Y, Ly E, Ezekowitz J, Ponikowski P, Lam CSP, O’Connor C, Blaustein RO, Roessig L, Temple T, Westerhout CM, Armstrong PW, Sandhu RK; VICTORIA Study Group.
Eur J Heart Fail. 2023 Sep 1. doi: 10.1002/ejhf.3021.

Cost-Effectiveness of Vericiguat in Patients With Heart Failure With Reduced Ejection Fraction: The VICTORIA Randomized Clinical Trial.
Chew DS, Li Y, Bigelow R, Cowper PA, Anstrom KJ, Daniels MR, Davidson-Ray L, Hernandez AF, O’Connor CM, Armstrong PW, Mark DB; VICTORIA Study Group.
Circulation. 2023 Sep 6. doi: 10.1161/CIRCULATIONAHA.122.063602.

Recurrent Hospitalizations and Response to Vericiguat in Heart Failure and Reduced Ejection Fraction.
Mentz RJ, Stebbins A, Butler J, Chiang CE, Ezekowitz JA, Hernandez AF, Hilkert R, Lam CSP, McDonald K, O’Connor CM, Pieske B, Ponikowski P, Roessig L, Sweitzer NK, Voors AA, Anstrom KJ, Armstrong PW; VICTORIA Study Group.
Jacc Heart Fail. 2024 Jan 22. doi: 10.1161/CIRCULATIONAHA.122.063602.

Diuretic Use and Outcomes in Patients with Heart Failure with Reduced Ejection Fraction: Insights from the VICTORIA trial.
Ezekowitz J, Alemayehu W, Edelmann F, Ponikowski P, Lam CSP, O’Connor CM, Butler J, Corda S, McMullan CJ, Westerhout CM, Voors AA, Mentz RJ, Armstrong PW; VICTORIA Study Group.
Eur J Heart Fail. 2024 Mar 7. doi: 10.1002/ejhf.3179.

Vericiguat and Cardiovascular Outcomes in Heart Failure by Baseline Diabetes Status: Insights From the VICTORIA Trial.
Khan MS, Butler J, Young R, Lewis BS, Escobedo J, Refsgaard J, Reyes E, Roessig L, Blaustein RO, Lam CSP, Voors AA, Ponikowski P, Anstrom KJ, Armstrong PW; VICTORIA Study Group.
JACC Heart Fail. 2024 Jun 11. doi: 10.1016/j.jchf.2024.05.007.

Biomarker Profiles Associated with Reverse Ventricular Remodelling in Patients with Heart Failure and a Reduced Ejection Fraction: Insights from the Echocardiographic Substudy of the VICTORIA trial.
Tromp J, Lam CSP, Alemayehu W, de Filippi CR, Melenovský V, Sliwa K, Lopatin Y, Arango JL, Bahit MC, Roessig L, O’Connor CM, Shah P, Westerhout CM, Voors AA, Pieske B, Armstrong PW; VICTORIA Study Group.
Eur J Heart Fail. 2024 Jul 30. doi: 10.1002/ejhf.3397.

Comparing Analytical Methods for Composite End Points in Clinical Trials: Insights from the Vericiguat Global Study in Subjects with Heart Failure With Reduced Ejection Fraction Trial.
Westerhout CM, Rathwell S, Anstrom KJ, Hernandez AF, Ponikowski P, Ezekowitz JA, Voors AA, Felker GM, Bakal JA, Blaustein RO, Nkulikiyinka R, O’Connor CM, Armstrong PW; VICTORIA Study Group.
J Card Fail. 2024 Sep 7. doi: 10.1016/j.cardfail.2024.08.038.

Projecting the benefit of vericiguat in PARADIGM-HF and DAPA-HF populations: Insights from the VICTORIA trial.
Kittipibul V, Mentz RJ, Young R, Butler J, Ezekowitz JA, Lam CSP, Ponikowski P, Voors A, Corda S, McMullan C, O’Connor CM, Anstrom KJ, Armstrong PW; VICTORIA Study Group.
ESC Heart Fail. 2024 Oct 22. doi: 10.1002/ehf2.15134